Drug Trial Radar · NCT04820452
A Study of IBI302 in Patients With nAMD
Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Apr 28, 2021
Primary completion
Jan 13, 2023
Study completion Jan 13, 2023
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
Low dose IBI302Biological
Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
High dose IBI302Biological
High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
AfliberceptDrug
Intraocular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The visual efficacy of IBI302Time frame: Baseline to week 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Innovent Biologics (Suzhou) Co,Ltd.
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.